These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27088018)

  • 41. Euglycemic diabetic ketoacidosis.
    Barski L; Eshkoli T; Brandstaetter E; Jotkowitz A
    Eur J Intern Med; 2019 May; 63():9-14. PubMed ID: 30910328
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.
    Henry RR; Thakkar P; Tong C; Polidori D; Alba M
    Diabetes Care; 2015 Dec; 38(12):2258-65. PubMed ID: 26486192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature.
    Lucero P; Chapela S
    Case Rep Crit Care; 2018; 2018():1747850. PubMed ID: 30364093
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
    da Silva PN; da Conceição RA; do Couto Maia R; de Castro Barbosa ML
    Medchemcomm; 2018 Aug; 9(8):1273-1281. PubMed ID: 30151080
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Canagliflozin use in Type I diabetes mellitus.
    Guthrie R
    Postgrad Med; 2017 Apr; 129(3):336-339. PubMed ID: 27918226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Canagliflozin-induced pancreatitis: a rare side effect of a new drug.
    Chowdhary M; Kabbani AA; Chhabra A
    Ther Clin Risk Manag; 2015; 11():991-4. PubMed ID: 26170677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes].
    Novik A V; García B C; Oliva I D
    Rev Med Chil; 2017 Mar; 145(3):393-396. PubMed ID: 28548198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol.
    Rendell MS
    Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis.
    Avram AM; Patel V; Taylor HC; Kirwan JP; Kalhan S
    Ann Pharmacother; 2001 Nov; 35(11):1381-7. PubMed ID: 11724088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions.
    D'Elia JA; Segal AR; Bayliss GP; Weinrauch LA
    Int J Nephrol Renovasc Dis; 2017; 10():153-158. PubMed ID: 28670136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis.
    Yu X; Zhang S; Zhang L
    Int J Endocrinol; 2018; 2018():7074868. PubMed ID: 30369948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
    Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
    Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
    Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
    Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2014 Dec; 69(12):692-9. PubMed ID: 25796788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
    Blau JE; Tella SH; Taylor SI; Rother KI
    Diabetes Metab Res Rev; 2017 Nov; 33(8):. PubMed ID: 28736981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.
    Clement M; Senior P
    Can Fam Physician; 2016 Sep; 62(9):725-8. PubMed ID: 27629668
    [No Abstract]   [Full Text] [Related]  

  • 57. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin.
    van Niekerk C; Wallace J; Takata M; Yu R
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30131409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Euglycemic Ketoacidosis in a Patient with Metastatic Non-Small-Cell Lung Adenocarcinoma and Concomitant Pulmonary Embolism.
    O'Neill RS; Tyack L; Freeman M; Hussein HS
    Case Rep Endocrinol; 2020; 2020():8882299. PubMed ID: 32832169
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol.
    Fortuna D; McCloskey LJ; Stickle DF
    Clin Chim Acta; 2016 Jan; 452():138-41. PubMed ID: 26569347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.